Pharmacological Insights in to Schizophrenia: Neurochemical Dysregulation, Disease Mechanisms and Future Therapeutic Strategies
TL;DR
Current understanding of the clinical features, etiological factors, biological mechanisms, and pharmacological management of schizophrenia is summarized, while emerging therapeutic targets that may guide future research and drug development are outlined.
Abstract
Schizophrenia is a chronic and heterogeneous neuropsychiatric condition that affects approximately one percent of the global population and is associated with substantial impairments in perception, cognition, emotional regulation, and social functioning. The disorder typically manifests during late adolescence or early adulthood and arises from a complex interaction between genetic susceptibility and environmental influences acting during critical stages of brain development. Clinically, schizophrenia is characterized by three major symptom clusters: positive symptoms, including hallucinations, delusions, and disorganized thinking; negative symptoms, such as reduced motivation, emotional blunting, social withdrawal, and diminished pleasure; and cognitive deficits involving attention, memory, learning, and executive processing. Traditional dopamine-centered theories primarily explain the emergence of positive symptoms but fail to adequately account for persistent negative and cognitive impairments. Contemporary research highlights the involvement of glutamatergic dysregulation, particularly N-methyl-D-aspartate receptor hypofunction, altered serotonergic signaling, and disrupted cortico–striatal–thalamic connectivity. Neuroimaging studies further demonstrate widespread structural and functional brain abnormalities, supporting a neurodevelopmental basis for the disorder. Increasing evidence also implicates neuroinflammatory processes, immune imbalance, and oxidative stress in the progression of neuronal dysfunction and white matter damage. Although currently available antipsychotic medications effectively alleviate positive symptoms in many patients, their clinical benefit is limited by adverse effects and insufficient efficacy against negative and cognitive domains. These limitations emphasize the necessity for safer and more comprehensive therapeutic strategies. This review summarizes current understanding of the clinical features, etiological factors, biological mechanisms, and pharmacological management of schizophrenia, while outlining emerging therapeutic targets that may guide future research and drug development.